Wave Life Sciences Q4 2024 Earnings Report

Wave Life Sciences EPS Results

• Actual EPS: $0.17
• Consensus EPS: -$0.17
• Beat/Miss: Beat by +$0.34
• One Year Ago EPS: N/A

Wave Life Sciences Revenue Results

• Actual Revenue: $83.75 million
• Expected Revenue: $25.60 million
• Beat/Miss: Beat by +$58.15 million
• YoY Revenue Growth: N/A

Wave Life Sciences Announcement Details

• Quarter: Q4 2024
• Date: 3/4/2025
• Time: Before Market Opens

Wave Life Sciences (NASDAQ:WVE), a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.